GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » 5-Year RORE %

Entheon Biomedical (XCNQ:ENBI) 5-Year RORE % : 0.00% (As of Nov. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Entheon Biomedical's 5-Year RORE % for the quarter that ended in Nov. 2023 was 0.00%.

The industry rank for Entheon Biomedical's 5-Year RORE % or its related term are showing as below:

XCNQ:ENBI's 5-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -7.26
* Ranked among companies with meaningful 5-Year RORE % only.

Entheon Biomedical 5-Year RORE % Historical Data

The historical data trend for Entheon Biomedical's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical 5-Year RORE % Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
5-Year RORE %
Get a 7-Day Free Trial - - - - -

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Entheon Biomedical's 5-Year RORE %

For the Biotechnology subindustry, Entheon Biomedical's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's 5-Year RORE % falls into.



Entheon Biomedical 5-Year RORE % Calculation

Entheon Biomedical's 5-Year RORE % for the quarter that ended in Nov. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( -4.1-0 )
=/-4.1
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Nov. 2023 and 5-year before.


Entheon Biomedical  (XCNQ:ENBI) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Entheon Biomedical 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines